



Merrimack
Investor Relations Department
One Kendall Square
Suite B7201
Cambridge, MA 02139
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: MACK


| | |
|---------------|----------------------------|
| Last Trade: | 13.26 |
| Trade Time: | 4:00 PM ET Oct 18, 2017 |
| Change: | 0.00 (0.000%) |
| Day Range | 13.10 - 13.45 |
| 52-Week Range | 11.30 - 67.90 |
| Volume | 114,154 |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. Our mission is to transform cancer care through the smart design and development of targeted solutions based on the deep understanding of cancer pathways and biological markers. All of our product candidates, including three in clinical studies and several others in preclinical development, fit into our three-pronged strategy of 1) understanding the biological problems we are trying to solve, 2) designing specific solution... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Oct 13, 2017
[Merrimack Commences Tender Offer for Any and All of its Outstanding 4.50% Convertible Senior Notes Due 2020](#)

Oct 10, 2017
[Merrimack Announces Settlement of Convertible Note Litigation](#)

Aug 31, 2017
[Merrimack Announces Date of One-for-Ten Reverse Stock Split](#)

Aug 14, 2017
[Merrimack Augments Executive Team with Appointment of Jean Franchi as Chief Financial Officer](#)

Aug 9, 2017
[Merrimack Reports Second Quarter 2017 Financial Results](#)

Financials [\[View all \]](#)

Jun 26, 2017
[Proxy Statement \(DEF 14A\)](#)

Aug 9, 2017
[Quarterly Report \(10-Q\)](#)

May 10, 2017
[Quarterly Report \(10-Q\)](#)